跳至主導覽 跳至搜尋 跳過主要內容

Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation

  • Jia Hung Ye
  • , Jung Chao
  • , Ming Ling Chang
  • , Wen Huang Peng
  • , Hao Yuan Cheng
  • , Jiunn Wang Liao
  • , Li Heng Pao*
  • *此作品的通信作者
  • Chang Gung University of Science and Technology
  • National Yang Ming Chiao Tung University
  • Liver Research Center
  • China Medical University Taichung
  • Chung Jen College of Nursing Health Science and Management
  • National Chung Hsing University

研究成果: 期刊稿件 › 文章 › 同儕審查

46 引文 斯高帕斯(Scopus)

摘要

Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake. In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate. Although several studies have examined the effectiveness of pentoxifylline (PTX) in NAFLD treatment, no results are available to verify the effectiveness of PTX in treating T2D associated with NAFLD. In this study, we developed a combined high-fat diet-induced obesity and low-dose streptozocin-induced hyperglycaemia mouse model to mimic the concurrent NAFLD and T2D pathological condition. By combining physiological assessments, pathological examinations, metabolomics studies on blood, urine, and liver, and measurements of gene and protein expression, we elucidated the effectiveness and the underlying mechanism of action of PTX in the hyperglycaemic and dyslipidaemic mice. Our results revealed that PTX ameliorated NAFLD in the hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Furthermore, the glycolysis pathway and branched-chain amino acid-related pathways in these mice were restored by PTX.

原文英語
文章編號33102
期刊Scientific Reports
卷6
DOIs
出版品狀態已出版 - 09 09 2016
對外發佈是

文獻附註

Publisher Copyright:
© 2016 The Author(s).

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation」主題。共同形成了獨特的指紋。

引用此